ANTX
AN2 Therapeutics, Inc.
There isn't enough reported data to score ANTX yet.
ANTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ANTX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ANTX PE Valuation
ANTX has no meaningful PE right now: it lost money over the past year.
ANTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ANTX's earnings, revenue and profitability to hold roughly steady.
ANTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.93 | +$0.19 |
| Q2 2026 | -$1.07 | +$0.17 |
| Q1 2026 | -$1.10 | +$0.41 |
| Q4 2025 | -$1.16 | +$0.56 |
| Q3 2025 | -$1.12 | +$0.84 |
| Q2 2025 | -$1.24 | +$0.94 |
| Q1 2025 | -$1.51 | +$1.00 |
| Q4 2024 | -$1.72 | +$1.02 |
ANTX is still losing money, but far less than before: $0.93 per share over the past year, against $4.56 at its worst in mid-2022.
ANTX Quarterly Revenue
ANTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.1M | +$273K |
| Q2 2026 | -$7M | +$601K |
| Q1 2026 | -$12.1M | -$1.4M |
| Q4 2025 | -$5.2M | +$37K |
| Q3 2025 | -$6.4M | +$5.6M |
| Q2 2025 | -$7.6M | +$6.8M |
| Q1 2025 | -$10.6M | +$7M |
| Q4 2024 | -$5.3M | +$11.8M |
ANTX has burned cash in almost every quarter: −$30M over the past year, against −$30M the year before.
ANTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +1.4M shares |
| 1 year | +52% | +15.8M shares |
| 3 years | +137% | +26.6M shares |
| 5 years | +228% | +32.1M shares |
ANTX has 46M diluted shares, up 52% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
ANTX Net Leverage
ANTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ANTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 28.0 | Neutral |
ANTX's weekly RSI is 50 (neutral) and its Stochastic is 28 (neutral).
ANTX PE vs Healthcare Sector
ANTX has no meaningful PE right now: it lost money over the past year.
ANTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.36 | 1.8% above |
| 20 week MA | $4.92 | 9.8% below |
| 50 week MA | $3.69 | 20% above |
| 100 week MA | $2.44 | 82% above |
| 200 week MA | $5.20 | 15% below |
ANTX's trend is mixed: it's above three of its five weekly moving averages, and 15% below its 200-week average.
ANTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $15.4 | $9.53 | -38% |
| 2023 | $9.53 | $20.5 | +115% |
| 2024 | $20.5 | $1.44 | -93% |
| 2025 | $1.44 | $1.14 | -21% |
| 2026 YTD | $1.14 | $4.44 | +289% |
ANTX's yearly returns have swung widely, from +115% in 2023 to −93% in 2024. It's up 289% so far in 2026.